BioCentury | Oct 31, 2016
Financial News

QR Pharma completes venture financing

QR Pharma Inc. , Berwyn, Pa. Business: Neurology Date completed: 2016-10-27 Type: Venture financing Raised: $800,000 Investors: Robin Hood Ventures; angel investors...
BioCentury | Jun 1, 2015
Financial News

QR Pharma completes venture financing

QR Pharma Inc. , Berwyn, Pa. Business: Neurology Date completed: 2015-05-26 Type: Venture financing Raised: $1.1 million Investors: Robin Hood Ventures; angel investors; company director Note: The company also converted $4.6 million of convertible debt into...
BioCentury | Mar 2, 2015
Company News

QR Pharma, Rockefeller University deal

...cell life of the HD cells. Posiphen is an amyloid precursor protein (APP) translation inhibitor. QR Pharma...
...treat Parkinson’s disease (PD) and traumatic brain injury (TBI). QR declined to disclose financial terms. QR Pharma Inc....
BioCentury | Oct 21, 2013
Company News

QR Pharma, University of California neurology news

...APP) translation inhibitor in models of concussion and blunt head trauma, two forms of TBI. QR Pharma...
...the grant is based on the compound's inhibitory effect on tau in rodents and humans. QR Pharma...
...TorreyPines Therapeutics Inc. , which merged with Raptor Pharmaceutical Corp. (NASDAQ:RPTP, Novato, Calif.) in 2009. QR Pharma Inc....
BioCentury | Jul 30, 2012
Clinical News

Bisnorcymserine: Phase I started

...Raptor in 2009 (see BioCentury, Nov. 24, 2008; Aug. 3, 2009 & Oct. 5, 2009). QR Pharma Inc....
BioCentury | Mar 12, 2012
Company News

QR Pharma, Michael J. Fox Foundation For Parkinson's Research neurology news

...Pharma received a $468,000 grant from the foundation to develop Posiphen to treat Parkinson's disease. QR Pharma...
...studies of the amyloid precursor protein (APP) translation inhibitor in a mouse model of PD. QR Pharma...
...Calif.) in 2009. Posiphen is also in Phase I/II testing to treat Alzheimer's disease (AD). QR Pharma Inc....
BioCentury | Oct 24, 2011
Product Development

Alzheimer's rewind

...development of a previous BACE1 inhibitor, CTS-2116 (ASP1702), after Phase I testing in AD. Meanwhile, QR Pharma Inc....
...San Diego, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Pfizer Inc. (NYSE:PFE), New York, N.Y. QR Pharma Inc....
...Sonexa Inc./ Zenyaku Kogyo Co. Ltd. ST101 Inducer of alternative cleavage of APP Ph II QR Pharma Inc./...
BioCentury | May 30, 2011
Emerging Company Profile

QR: Power of positivity

...it failed to show a benefit in three Phase III trials in AD. According to QR Pharma...
...own programs." TorreyPines went on the merge with Raptor Pharmaceutical Corp. in 2009. Last year, QR Pharma...
...Aging , Bethesda, Md. QR Pharma Inc. , Berwyn, Pa. Raptor Pharmaceutical Corp. (NASDAQ:RPTP), Novato, Calif. Sidebars QR Pharma Inc....
BioCentury | Jun 7, 2010
Financial News

QR Pharma completes venture financing

QR Pharma Inc. , Radnor, Pa. Business: Neurology Date completed: 6/2/10 Type: Venture financing Raised: $2.5 million Investors: BioAdvance; Ben Franklin Technology Partners; angel investors; private investors WIR Staff Neurology...
BioCentury | Feb 22, 2010
Clinical News

Posiphen: Phase II started

...worldwide rights to Posiphen from TorreyPines Therapeutics Inc. , which merged with Raptor last year. QR Pharma Inc....
Items per page:
1 - 10 of 11
BioCentury | Oct 31, 2016
Financial News

QR Pharma completes venture financing

QR Pharma Inc. , Berwyn, Pa. Business: Neurology Date completed: 2016-10-27 Type: Venture financing Raised: $800,000 Investors: Robin Hood Ventures; angel investors...
BioCentury | Jun 1, 2015
Financial News

QR Pharma completes venture financing

QR Pharma Inc. , Berwyn, Pa. Business: Neurology Date completed: 2015-05-26 Type: Venture financing Raised: $1.1 million Investors: Robin Hood Ventures; angel investors; company director Note: The company also converted $4.6 million of convertible debt into...
BioCentury | Mar 2, 2015
Company News

QR Pharma, Rockefeller University deal

...cell life of the HD cells. Posiphen is an amyloid precursor protein (APP) translation inhibitor. QR Pharma...
...treat Parkinson’s disease (PD) and traumatic brain injury (TBI). QR declined to disclose financial terms. QR Pharma Inc....
BioCentury | Oct 21, 2013
Company News

QR Pharma, University of California neurology news

...APP) translation inhibitor in models of concussion and blunt head trauma, two forms of TBI. QR Pharma...
...the grant is based on the compound's inhibitory effect on tau in rodents and humans. QR Pharma...
...TorreyPines Therapeutics Inc. , which merged with Raptor Pharmaceutical Corp. (NASDAQ:RPTP, Novato, Calif.) in 2009. QR Pharma Inc....
BioCentury | Jul 30, 2012
Clinical News

Bisnorcymserine: Phase I started

...Raptor in 2009 (see BioCentury, Nov. 24, 2008; Aug. 3, 2009 & Oct. 5, 2009). QR Pharma Inc....
BioCentury | Mar 12, 2012
Company News

QR Pharma, Michael J. Fox Foundation For Parkinson's Research neurology news

...Pharma received a $468,000 grant from the foundation to develop Posiphen to treat Parkinson's disease. QR Pharma...
...studies of the amyloid precursor protein (APP) translation inhibitor in a mouse model of PD. QR Pharma...
...Calif.) in 2009. Posiphen is also in Phase I/II testing to treat Alzheimer's disease (AD). QR Pharma Inc....
BioCentury | Oct 24, 2011
Product Development

Alzheimer's rewind

...development of a previous BACE1 inhibitor, CTS-2116 (ASP1702), after Phase I testing in AD. Meanwhile, QR Pharma Inc....
...San Diego, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Pfizer Inc. (NYSE:PFE), New York, N.Y. QR Pharma Inc....
...Sonexa Inc./ Zenyaku Kogyo Co. Ltd. ST101 Inducer of alternative cleavage of APP Ph II QR Pharma Inc./...
BioCentury | May 30, 2011
Emerging Company Profile

QR: Power of positivity

...it failed to show a benefit in three Phase III trials in AD. According to QR Pharma...
...own programs." TorreyPines went on the merge with Raptor Pharmaceutical Corp. in 2009. Last year, QR Pharma...
...Aging , Bethesda, Md. QR Pharma Inc. , Berwyn, Pa. Raptor Pharmaceutical Corp. (NASDAQ:RPTP), Novato, Calif. Sidebars QR Pharma Inc....
BioCentury | Jun 7, 2010
Financial News

QR Pharma completes venture financing

QR Pharma Inc. , Radnor, Pa. Business: Neurology Date completed: 6/2/10 Type: Venture financing Raised: $2.5 million Investors: BioAdvance; Ben Franklin Technology Partners; angel investors; private investors WIR Staff Neurology...
BioCentury | Feb 22, 2010
Clinical News

Posiphen: Phase II started

...worldwide rights to Posiphen from TorreyPines Therapeutics Inc. , which merged with Raptor last year. QR Pharma Inc....
Items per page:
1 - 10 of 11